TY - JOUR
T1 - Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia–a study of the Acute Leukemia Working Party of the EBMT
AU - Heinicke, Thomas
AU - Labopin, Myriam
AU - Polge, Emmanuelle
AU - Stelljes, Matthias
AU - Ganser, Arnold
AU - Tischer, Johanna
AU - Brecht, Arne
AU - Kröger, Nicolaus
AU - Beelen, Dietrich W.
AU - Scheid, Christof
AU - Bethge, Wolfgang
AU - Dreger, Peter
AU - Bunjes, Donald
AU - Wagner, Eva
AU - Platzbecker, Uwe
AU - Savani, Bipin N.
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients <55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (<55 years) patients a more intense regimen might be used whereas in older (≥55 years) patients the focus might be more on tolerability.
AB - The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients <55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (<55 years) patients a more intense regimen might be used whereas in older (≥55 years) patients the focus might be more on tolerability.
KW - Relapsed/refractory AML
KW - clinical results
KW - sequential conditioning regimens
UR - http://www.scopus.com/inward/record.url?scp=85092481082&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1827248
DO - 10.1080/10428194.2020.1827248
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33040622
AN - SCOPUS:85092481082
SN - 1042-8194
VL - 62
SP - 399
EP - 409
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -